Gilead Sciences logo

Gilead Sciences share price today

(NASDAQ: GILD)

Gilead Sciences share price is $92.92 & ₹8,036.65 as on 24 Jan 2025, 2.30 'hrs' IST

$92.92

-0.12

(-0.13%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Gilead Sciences share price in Dollar and Rupees. Guide to invest in Gilead Sciences stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Gilead Sciences, along with analyst recommendations, forecasts, and comprehensive financials.

Gilead Sciences share price movements

  • Today's Low: $92.21
    Today's High: $93.26

    Day's Volatility :1.13%

  • 52 Weeks Low: $62.07
    52 Weeks High: $98.90

    52 Weeks Volatility :37.24%

Gilead Sciences Returns

PeriodGilead Sciences Inc.Sector (Health Care)S&P500
3 Months
4.54%
-4.8%
4.8%
6 Months
20.82%
-5.1%
12.1%
1 Year
15.97%
2.5%
25.0%
3 Years
35.15%
10.2%
38.0%

Gilead Sciences Key Statistics

in dollars & INR

Previous Close
$93.04
Open
$93.03
Today's High
$93.26
Today's Low
$92.21
Market Capitalization
$115.9B
Today's Volume
$6.6M
52 Week High
$98.9
52 Week Low
$62.07
Revenue TTM
$28.3B
EBITDA
$13.9B
Earnings Per Share (EPS)
$0.09
PE Ratio
1032.89
Dividend Yield
3.35%
Profit Margin
0.45%
Quarterly Earnings Growth YOY
-0.42%
Return On Equity TTM
0.56%

How to invest in Gilead Sciences Stock (GILD) from India?

It is very easy for Indian residents to invest directly in Gilead Sciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Gilead Sciences stock in both Indian Rupees (INR) and US Dollars (USD). Search for Gilead Sciences or GILD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Gilead Sciences or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Gilead Sciences shares which would translate to 0.009 fractional shares of Gilead Sciences as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Gilead Sciences, in just a few clicks!

Returns in Gilead Sciences for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Gilead Sciences investment value today

Current value as on today

₹1,19,927

Returns

₹19,927

(+19.93%)

Returns from Gilead Sciences Stock

₹15,817 (+15.82%)

Dollar Returns

₹4,109 (+4.11%)

Indian investors sentiment towards Gilead Sciences

26%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Gilead Sciences on INDmoney from India has grown in the last 30 days as on Jan 24, 2025. 26% more investors are searching Gilead Sciences in the last 30 days versus the previous period.

Global Institutional Holdings in Gilead Sciences

  • Renaissance Technologies Corp

    0.34%

Analyst Recommendation on Gilead Sciences

Hold

    47%Buy

    52%Hold

    0%Sell

Based on 38 Wall street analysts offering stock ratings for Gilead Sciences(by analysts ranked 0 to 5 stars)

Based on 38 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
19
Hold
20
19
17
Sell
0
1
1

Analyst Forecast on Gilead Sciences

What analysts predicted

Upside of 7.57%

Target:

$99.96

Current:

$92.92

Insights on Gilead Sciences

  • Price Movement

    In the last 6 months, GILD stock has moved up by 26.6%
  • Increasing Revenue

    Gilead Sciences Inc. has shown a positive revenue trend over the last three quarters. Revenue increased from $6.68 billion to $7.54 billion, resulting in an average growth rate of 5.8% per quarter.
  • Decreasing Net Profit

    Gilead Sciences Inc. has experienced a decline in net profit over the last two quarters. In the most recent quarter, the net profit decreased from $1.61 billion to $1.25 billion. This represents an average decrease of 22.4% per quarter.
  • GILD vs LLY (1 yr)

    In the last 1 year, Eli Lilly And Company has given 19.0% return, outperforming this stock by 2.0%
  • GILD vs LLY (3 yr)

    In the last 3 years, Eli Lilly And Company has given 213.6% return, outperforming this stock by 177.9%
  • Price to Sales

    Gilead Sciences Inc. has a Price-to-Sales Ratio of 4.1, meaning that investors are willing to pay $4.1 for every $1 of the company's sales. In contrast, for Eli Lilly And Company, investors are paying significantly more at $16.9 for every $1 of sales. This indicates that Gilead shares are priced lower relative to its sales compared to Eli Lilly.

Gilead Sciences Financials in INR & Dollars

FY18Y/Y Change
Revenue
$22.1B
↓ 15.24%
Net Income
$5.5B
↑ 17.87%
Net Profit Margin
24.65%
↑ 6.92%
FY19Y/Y Change
Revenue
$22.4B
↑ 1.46%
Net Income
$5.4B
↓ 1.26%
Net Profit Margin
23.99%
↓ 0.66%
FY20Y/Y Change
Revenue
$24.7B
↑ 9.98%
Net Income
$89.0M
↓ 98.35%
Net Profit Margin
0.36%
↓ 23.63%
FY21Y/Y Change
Revenue
$27.3B
↑ 10.6%
Net Income
$6.2B
↑ 6894.38%
Net Profit Margin
22.8%
↑ 22.44%
FY22Y/Y Change
Revenue
$27.3B
↓ 0.09%
Net Income
$4.6B
↓ 26.23%
Net Profit Margin
16.83%
↓ 5.97%
FY23Y/Y Change
Revenue
$27.1B
↓ 0.6%
Net Income
$5.7B
↑ 23.37%
Net Profit Margin
20.89%
↑ 4.06%
Q2 FY23Q/Q Change
Revenue
$6.6B
↑ 3.89%
Net Income
$1.0B
↑ 3.47%
Net Profit Margin
15.84%
↓ 0.06%
Q3 FY23Q/Q Change
Revenue
$7.1B
↑ 6.83%
Net Income
$2.2B
↑ 108.61%
Net Profit Margin
30.92%
↑ 15.08%
Q4 FY23Q/Q Change
Revenue
$7.1B
↑ 0.92%
Net Income
$1.4B
↓ 34.45%
Net Profit Margin
20.08%
↓ 10.84%
Q1 FY24Q/Q Change
Revenue
$6.7B
↓ 6.03%
Net Income
$-4.2B
↓ 391.81%
Net Profit Margin
-62.37%
↓ 82.45%
Q2 FY24Q/Q Change
Revenue
$6.9B
↑ 3.93%
Net Income
$1.6B
↓ 138.71%
Net Profit Margin
23.23%
↑ 85.6%
Q3 FY24Q/Q Change
Revenue
$7.5B
↑ 8.58%
Net Income
$1.3B
↓ 22.37%
Net Profit Margin
16.61%
↓ 6.62%
FY18Y/Y Change
Profit
$17.3B
↓ 20.53%
FY19Y/Y Change
Profit
$17.8B
↑ 2.89%
FY20Y/Y Change
Profit
$20.1B
↑ 13.18%
FY21Y/Y Change
Profit
$20.7B
↑ 2.92%
FY22Y/Y Change
Profit
$21.6B
↑ 4.44%
FY23Y/Y Change
Profit
$27.1B
↑ 25.4%
Q2 FY23Q/Q Change
Profit
$5.2B
↑ 4.16%
Q3 FY23Q/Q Change
Profit
$5.5B
↑ 6.36%
Q4 FY23Q/Q Change
Profit
$5.6B
↑ 1.28%
Q1 FY24Q/Q Change
Profit
$5.1B
↓ 7.58%
Q2 FY24Q/Q Change
Profit
$5.4B
↑ 5.28%
Q3 FY24Q/Q Change
Profit
$6.0B
↑ 10.47%
FY18Y/Y Change
Operating Cash Flow
$8.4B
↓ 29.4%
Investing Cash Flow
$14.4B
↓ 189.33%
Financing Cash Flow
$-12.3B
↓ 463.04%
FY19Y/Y Change
Operating Cash Flow
$9.1B
↑ 8.86%
Investing Cash Flow
$-7.8B
↓ 154.45%
Financing Cash Flow
$-7.6B
↓ 38.03%
FY20Y/Y Change
Operating Cash Flow
$8.2B
↓ 10.67%
Investing Cash Flow
$-14.6B
↑ 86.96%
Financing Cash Flow
$770.0M
↓ 110.09%
FY21Y/Y Change
Operating Cash Flow
$11.4B
↑ 39.37%
Investing Cash Flow
$-3.1B
↓ 78.58%
Financing Cash Flow
$-8.9B
↓ 1252.86%
FY22Y/Y Change
Operating Cash Flow
$9.1B
↓ 20.31%
Investing Cash Flow
$-2.5B
↓ 21.24%
Financing Cash Flow
$-6.5B
↓ 27.13%
FY23Y/Y Change
Operating Cash Flow
$8.0B
↓ 11.75%
Investing Cash Flow
$-2.3B
↓ 8.15%
Financing Cash Flow
$-5.1B
↓ 20.78%
Q2 FY23Q/Q Change
Operating Cash Flow
$2.3B
↑ 34.0%
Investing Cash Flow
$-483.0M
↓ 41.53%
Financing Cash Flow
$-1.1B
↓ 21.69%
Q3 FY23Q/Q Change
Operating Cash Flow
$1.8B
↓ 24.86%
Investing Cash Flow
$-229.0M
↓ 52.59%
Financing Cash Flow
$-1.5B
↑ 37.87%
Q4 FY23Q/Q Change
Operating Cash Flow
$2.2B
↑ 23.52%
Investing Cash Flow
$-727.0M
↑ 217.47%
Financing Cash Flow
$-1.1B
↓ 27.6%
Q1 FY24Q/Q Change
Operating Cash Flow
$2.2B
↑ 2.31%
Investing Cash Flow
$-2.2B
↑ 203.58%
Financing Cash Flow
$-1.4B
↑ 23.84%

Gilead Sciences Technicals Summary

Sell

Neutral

Buy

Gilead Sciences is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Gilead Sciences Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gilead Sciences Inc. logo
-1.45%
20.82%
15.97%
35.15%
45.76%
Eli Lilly And Company logo
-5.06%
-6.29%
20.13%
214.87%
445.14%
Johnson & Johnson logo
-0.21%
-9.57%
-8.96%
-13.34%
-2.34%
Merck & Co. Inc. logo
-3.24%
-22.86%
-19.56%
21.61%
12.23%
Novo Nordisk A/s logo
-8.08%
-36.42%
-23.76%
69.34%
168.75%
Abbvie Inc logo
-4.76%
-7.83%
3.35%
28.24%
103.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gilead Sciences Inc. logo
1032.89
1032.89
0.53
4.41
0.01
0.12
0.03
14.83
Eli Lilly And Company logo
81.34
81.34
0.71
12.98
0.65
0.14
0.01
15.83
Johnson & Johnson logo
24.33
24.33
0.86
9.96
0.21
0.08
0.03
29.14
Merck & Co. Inc. logo
20.48
20.48
0.07
7.68
0.28
0.11
0.03
17.58
Novo Nordisk A/s logo
26.92
26.92
1.28
23.06
0.89
0.21
0.02
27.07
Abbvie Inc logo
59.93
59.93
0.41
10.77
0.56
0.08
0.04
3.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gilead Sciences Inc. logo
Hold
$115.9B
45.76%
1032.89
0.45%
Eli Lilly And Company logo
Buy
$678.1B
445.14%
81.34
20.48%
Johnson & Johnson logo
Buy
$356.7B
-2.34%
24.33
16.74%
Merck & Co. Inc. logo
Buy
$247.7B
12.23%
20.48
19.23%
Novo Nordisk A/s logo
Buy
$352.9B
168.75%
26.92
35.01%
Abbvie Inc logo
Buy
$305.0B
103.13%
59.93
9.22%

Gilead Sciences Dividend announcements

  • Gilead Sciences Dividends December, 2024

    In the quarter ending December,2024. Gilead Sciences has declared dividend of $0.77

    Read More

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Organization
Gilead Sciences
Employees
18000
CEO
Mr. Daniel P. O'Day
Industry
Health Technology

Management People of Gilead Sciences

NameTitle
Mr. Daniel P. O'Day
Chairman & CEO
Mr. Andrew D. Dickinson
Chief Financial Officer
Ms. Deborah H. Telman J.D.
Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
Ms. Johanna Mercier
Chief Commercial Officer
Ms. Sandra Patterson
Senior VP, Corporate Controller & Principal Accounting Officer
Ms. Jacquie Ross C.F.A.
Vice President of Investor Relations
Ms. Jyoti K. Mehra
Executive Vice President of Human Resources
Dr. Linda Slanec Higgins Ph.D.
Senior Vice President of Research, Innovation & Portfolio
Dr. Rudolf Ertl
Senior Vice President of Commercial Operations of Australia, Canada, Europe
Dr. Flavius Martin M.D.
Executive Vice President of Research

Important FAQs about investing in Gilead Sciences (GILD) from India :

What is Gilead Sciences share price today?

Gilead Sciences share price today stands at $92.92, Open: $93.03 ; Previous Close: $93.04 ; High: $93.26 ; Low: $92.21 ; 52 Week High: $98.90 ; 52 Week Low: $62.07. The stock opens at $93.03, after a previous close of $93.04. The stock reached a daily high of $93.26 and a low of $92.21, with a 52-week high of $98.90 and a 52-week low of $62.07.

Can Indians buy Gilead Sciences shares?

Yes, Indians can invest in the Gilead Sciences (GILD) from India.

With INDmoney, you can buy Gilead Sciences at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Gilead Sciences at zero transaction cost.

How can I buy Gilead Sciences shares from India?

It is very easy to buy Gilead Sciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Gilead Sciences be purchased?

Yes, you can buy fractional shares of Gilead Sciences with INDmoney app.

What are the documents required to start investing in Gilead Sciences stocks?

To start investing in Gilead Sciences, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Gilead Sciences

Today’s highest price of Gilead Sciences (GILD) is $93.26.

Today’s lowest price of Gilead Sciences (GILD) is $92.21.

What is today's market capitalisation of Gilead Sciences

Today's market capitalisation of Gilead Sciences GILD is 115.9B

What is the 52 Week High and Low Range of Gilead Sciences

  • 52 Week High

    $98.90

  • 52 Week Low

    $62.07

What are the historical returns of Gilead Sciences?

  • 1 Month Returns

    -1.45%

  • 3 Months Returns

    20.82%

  • 1 Year Returns

    15.97%

  • 5 Years Returns

    45.76%

Who is the Chief Executive Officer (CEO) of Gilead Sciences

Mr. Daniel P. O'Day is the current Chief Executive Officer (CEO) of Gilead Sciences.